These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30930026)

  • 1. Promising new combination therapy for non-GCB DLBCL.
    Gourd E
    Lancet Oncol; 2019 May; 20(5):e245. PubMed ID: 30930026
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
    J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 4. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
    Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
    J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Connors JM
    Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Wanner D; Bohn JP; Rudzki J; Stockhammer G; Steurer M
    Ann Hematol; 2019 Jan; 98(1):205-207. PubMed ID: 29804266
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
    Gao Y; Xie Y; Liu L; Xue H; Hou M; Zhang M; Zhou Z; Guo P; Yao H; Shao Z; Xie X; Zhu J
    Minerva Med; 2021 Apr; 112(2):310-312. PubMed ID: 31317691
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
    Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
    Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
    Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
    Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
    Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
    Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
    Campiotti L; Suter MB; De Palma D; Proserpio I; Uccella S; Squizzato A
    Hematol Oncol; 2019 Aug; 37(3):308-309. PubMed ID: 30933368
    [No Abstract]   [Full Text] [Related]  

  • 16. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
    Zhang WH; Li GY; Ma YJ; Li ZC; Zhu Y; Chang J; Hao SG; Tao R
    Ann Hematol; 2018 Oct; 97(10):1809-1816. PubMed ID: 29754271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy.
    Yokoo M; Kojima K; Sano H; Kai K; Arakawa F; Ohshima K; Matsunaga T; Kimura S
    Ann Hematol; 2019 Jun; 98(6):1501-1503. PubMed ID: 30406822
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
    Guidez S; Lacotte-Thierry L; Tomowiak C; Princet I; Dreyfus B; Olivier G; Fleck E; Corby A; Motard C; Barrier J; Machet A; Le Dû K; Debiais-Delpech C; Chabin M; Leleu X; Guilhot J; Delwail V
    Br J Haematol; 2019 Sep; 186(6):e175-e178. PubMed ID: 31309541
    [No Abstract]   [Full Text] [Related]  

  • 19. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
    Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
    Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
    Pang A; Au-Yeung R; Leung RYY; Kwong YL
    Ann Hematol; 2019 Oct; 98(10):2433-2436. PubMed ID: 31446456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.